Q4 2025 Curis Inc Earnings Call Transcript
Key Points
- Curis Inc (CRIS) reported a net income of $19.4 million for the fourth quarter of 2025, a significant improvement from a net loss of $9.6 million in the same period of 2024.
- The company is making steady progress in its TakeAim Lymphoma study, which is expected to support accelerated submissions in both the US and Europe.
- Curis Inc (CRIS) has begun activating clinical sites in the US and Europe for its proof-of-concept study in CLL, with initial data expected at the ASH Annual Meeting in December.
- The company presented promising data for its ongoing AML triplet study, with five of eight evaluable patients achieving MRD conversion.
- Curis Inc (CRIS) has a solid financial position, with cash and cash equivalents expected to support planned operations into the second half of 2027.
- Curis Inc (CRIS) reported a net loss of $7.6 million for the year ended December 31, 2025, despite the quarterly profit.
- The company will have no meaningful revenue in 2026 due to the sale of its Erivedge royalty stream to Oberland.
- Enrollment in the PCNSL study is challenging due to the rarity of the condition, with patient recruitment being described as 'choppy'.
- The company is prioritizing NHL over AML, which may delay progress in AML research and development.
- Curis Inc (CRIS) has not yet disclosed the dosing of the first patient in its CLL study, indicating potential delays in study initiation.
Good afternoon, ladies and gentlemen, and welcome to the Curis fourth-quarter 2025 business update conference call. (Operator Instructions) This call is being recorded today, Thursday, March 19, 2026.
I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Please go ahead.
Thank you, and welcome to Curis' fourth-quarter 2025 business update call. Before we begin, I'd like to encourage everyone to go to the Investors section of our website at www.curis.com to find our fourth quarter 2025 business update press release and related financial tables.
I would also like to remind everyone that during the call, we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.
Joining me today on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
